Enurace 50mg tablets (pack of 100)

Enurace Tablets For Dogs 50mg 100 Pack

Enurace 50mg Tablets For Dogs are used to help address urinary incontinence in dogs. This is caused when the urethral sphincter mechanism becomes incompetent due to hospitalisation or surgery for ovariohysterectomy, which leaves these muscles weak and unable to support full thickness voiding during urination without leakage.

Enurace for dogs is a 50mg white round with a break line on one side. The active ingredient is Ephedrine. Available in a 100 pack.

How To Buy Enurace

Enurace tablets are a prescription-only medication. This means that before you complete your purchase, you are required to upload a prescription through our online portal. Once our team has confirmed you've ordered the right medication for your dog we will send out your order. It's a simple process that means you can buy Enurace online instead of going to your vet every month.

How To Use Enurace

Enurace is for oral administration only. A starting dose of 2mg per kg of body weight daily, divided into two doses, is recommended. Dogs can be dosed as per the following table:

Enurace Special Precautions

• Do not use the product in dogs under 20 kilogram of body weight. 

• Do not use it on dogs with glaucoma.

• Do not use in cases of hypersensitivity to the active substance or to any of the excipients. 

• Not suitable for the treatment of inappropriate urination due to behaviour problems.

• Ephedrine may interact with other sympathomimetics.

• Ephedrine may enhance glucocorticoid metabolism. 

• Vomiting has been reported very rarely in spontaneous reports.

Target species

Dog (ovariohysterectomised female dogs).

Indications for use, specifying the target species

Treatment of urinary incontinence caused by urethral sphincter mechanism incompetence in ovariohysterectomised female dogs.

Contraindications

• Do not use in dogs with glaucoma.
• Do not use in cases of hypersensitivity to the active substance or to any of the excipients.

Special warnings for each target species

This product is not suitable for treatment of inappropriate urination due to behaviour problems.

Special precautions for use

Special precautions for use in animals

Do not use the product in dogs under 20 kilogram of bodyweight.

As ephedrine is an alpha- and beta-adrenergic receptor agonist, the product should be used with caution in dogs with cardiovascular disease and only after a comprehensive risk/benefit analysis by the attending veterinarian.

The dog’s cardiovascular functionality should be carefully assessed before the start of the treatment with the product and it should be periodically monitored during the treatment.

In addition, a similar approach should be adopted in animals suffering from partial urethral obstruction, hypertension, diabetes mellitus, hyperadrenocorticism, hyperthyroidism or other metabolic disorders. It should be mentioned that the polyuria/polydipsia (PU/PD) frequently accompanying the aforementioned conditions may be falsely diagnosed as urinary incontinence.

Special precautions to be taken by the person administering the veterinary medicinal product to animals

Ephedrine hydrochloride could be toxic if ingested. Adverse effects may include insomnia and nervousness, dizziness, headache, increased blood pressure, increased sweating and nausea.

Ingestion may be fatal, especially in children. To avoid accidental ingestion, the product must be used and kept out of the reach of children. Always replace the cap securely after use.

In case of accidental ingestion, most importantly by children, seek medical advice immediately and show the package leaflet or the label to the physician.

It is strongly recommended that pregnant women should wear gloves for administration.

Wash hands after administration.

Adverse reactions (frequency and seriousness)

• Cardiovascular effects like tachycardia, atrial fibrillation, stimulation of the heart activity; and vasoconstriction.
• Stimulation of the central nervous system leading to sleeplessness, excitation, anxiety and muscle tremors.
• Panting.
• Mydriasis.
• Cystitis.
• Bronchodilatation and decrease of mucus release in the respiratory mucosal membranes.
• Reduction of the motility and tone of the intestinal wall.

Due to the nature of ephedrine the mentioned effects can occur at the recommended therapeutic dose, with anxiety and cardiovascular effects being the most prevalent. In 10% of the treatments, side effects have been observed in efficacy studies.

Vomiting has been reported very rarely in spontaneous reports.

The frequency of adverse reactions is defined using the following convention:

• very common (more than 1 in 10 animals treated displaying adverse reaction(s)
• common (more than 1 but less than 10 animals in 100 animals treated)
• uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
• rare (more than 1 but less than 10 animals in 10,000 animals treated)
• very rare (less than 1 animal in 10,000 animals treated, including isolated reports).

Use during pregnancy, lactation or lay

Not applicable.

Interaction with other medicinal products and other forms of interaction

• Ephedrine may interact with other sympathomimetics.
• Ephedrine may enhance glucocorticoid metabolism.
• Concomitant use with MAO-inhibitors may cause hypertension.
• Ephedrine can enhance the activity of products of the same class as theophylline.
• Volatile anaesthetics may enhance the sensitivity of the myocardium to the cardiovascular effects of ephedrine.
• Concomitant use with cardiac glycosides, quinine and tricyclic antidepressants can cause arrhythmias.
• Vascular constrictions can occur after concomitant treatment with ergot alkaloids and oxytocin.
• Substances leading to an increase in pH of the urine are able to prolong the excretion of ephedrine, whereas substances leading to a decrease in pH of the urine are able to accelerate the excretion of ephedrine.